Search

Your search keyword '"Szubert, Alex"' showing total 28 results

Search Constraints

Start Over You searched for: Author "Szubert, Alex" Remove constraint Author: "Szubert, Alex"
28 results on '"Szubert, Alex"'

Search Results

2. COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

3. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

9. Supplementary Methods, References, Legends for Table 1 and Figure 1 from Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma

11. Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial

13. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

14. Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

15. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa

16. Adjunctive rifampicin for Staphylococcus aureusbacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial

17. Sequential Immunomodulatory Drug (IMiD) and Proteosome Inhibitor Therapy Improves Response Rates in Newly Diagnosed Multiple Myeloma: Preliminary Results From the Myeloma XI Trial

18. MRC Myeloma IX, 6 Year Median Follow-up (FU) Highlights the Importance of Long-Term FU in Myeloma Clinical Trials and Differential Effects of Thalidomide in High- and Low-Risk Disease

20. Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma

21. Heterogeneity in the Prognostic Significance of 12p Deletion and Chromosome 5 Amplification in Multiple Myeloma

22. Thalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) and Overall Survival (OS) of Myeloma Patients When Effective Relapse Treatments Are Used: MRC Myeloma IX Results

24. The Addition of Thalidomide to the Induction Treatment of Newly Presenting Myeloma Patients Increases the CR Rate Which Is Likely to Translate Into Improved PFS and OS.

26. Maintenance Thalidomide May Improve Progression Free but Not Overall Survival; Results from the Myeloma IX Maintenance Randomisation

28. The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance.

Catalog

Books, media, physical & digital resources